Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE6.2000
- TODAY'S CHANGE (%)0.3100 (5.2632%)
- Bid / Lots6.0400/ 4
- Ask / Lots6.4000/ 7
- Open / Previous Close5.8700 / 5.8900
- Day Range
- 52 Week Range
- Volume3,588,472
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 2185 | 5.87 |
| 09:34 ET | 3400 | 5.99 |
| 09:38 ET | 630 | 5.83 |
| 09:43 ET | 100 | 5.8356 |
| 09:45 ET | 100 | 5.84 |
| 09:50 ET | 400 | 5.81 |
| 09:52 ET | 448 | 5.8003 |
| 09:54 ET | 274 | 5.8154 |
| 09:56 ET | 996 | 5.81 |
| 09:57 ET | 100 | 5.82 |
| 10:08 ET | 1200 | 5.845 |
| 10:10 ET | 596 | 5.8608 |
| 10:12 ET | 1300 | 5.9 |
| 10:14 ET | 10783 | 5.99 |
| 10:15 ET | 1515 | 5.97 |
| 10:17 ET | 2838 | 5.98 |
| 10:19 ET | 1100 | 5.96 |
| 10:21 ET | 4172 | 5.97 |
| 10:24 ET | 650 | 5.99 |
| 10:26 ET | 200 | 5.9653 |
| 10:28 ET | 3809 | 6.005 |
| 10:30 ET | 10198 | 6.035 |
| 10:32 ET | 2120 | 6.025 |
| 10:33 ET | 1100 | 6.03 |
| 10:35 ET | 2287 | 6.0001 |
| 10:37 ET | 1610 | 5.97 |
| 10:39 ET | 100 | 5.96 |
| 10:42 ET | 3249 | 5.905 |
| 10:44 ET | 1200 | 5.87 |
| 10:46 ET | 461 | 5.85 |
| 10:50 ET | 1111 | 5.87 |
| 10:53 ET | 760 | 5.87 |
| 10:57 ET | 100 | 5.83 |
| 11:00 ET | 100 | 5.82 |
| 11:04 ET | 1237 | 5.86 |
| 11:06 ET | 1751 | 5.86 |
| 11:08 ET | 100 | 5.865 |
| 11:09 ET | 609 | 5.8 |
| 11:11 ET | 3040 | 5.78 |
| 11:15 ET | 1007 | 5.7701 |
| 11:18 ET | 4200 | 5.83 |
| 11:20 ET | 5231 | 5.83 |
| 11:22 ET | 2300 | 5.8201 |
| 11:26 ET | 971 | 5.82 |
| 11:29 ET | 1319 | 5.83 |
| 11:33 ET | 1225 | 5.83 |
| 11:36 ET | 6448 | 5.83 |
| 11:40 ET | 200 | 5.82 |
| 11:42 ET | 100 | 5.82 |
| 11:44 ET | 2877 | 5.87 |
| 11:47 ET | 100 | 5.855 |
| 11:49 ET | 2294 | 5.87 |
| 11:51 ET | 701 | 5.89 |
| 11:54 ET | 100 | 5.86 |
| 11:56 ET | 200 | 5.91 |
| 11:58 ET | 2295 | 5.9 |
| 12:00 ET | 100 | 5.905 |
| 12:02 ET | 200 | 5.905 |
| 12:03 ET | 100 | 5.89 |
| 12:05 ET | 100 | 5.87 |
| 12:07 ET | 2800 | 5.93 |
| 12:09 ET | 4505 | 5.945 |
| 12:12 ET | 250 | 5.9422 |
| 12:14 ET | 2542 | 5.97 |
| 12:16 ET | 3372 | 5.965 |
| 12:18 ET | 6199 | 5.97 |
| 12:20 ET | 894 | 5.975 |
| 12:21 ET | 100 | 5.96 |
| 12:25 ET | 778 | 6.0175 |
| 12:27 ET | 100 | 5.985 |
| 12:30 ET | 1466 | 5.98 |
| 12:32 ET | 200 | 6.005 |
| 12:34 ET | 335 | 5.98 |
| 12:36 ET | 200 | 6.01 |
| 12:38 ET | 500 | 5.98 |
| 12:39 ET | 2026 | 5.97 |
| 12:41 ET | 1460 | 5.97 |
| 12:43 ET | 226 | 5.97 |
| 12:45 ET | 1269 | 6 |
| 12:50 ET | 800 | 5.99 |
| 12:52 ET | 900 | 5.97 |
| 12:54 ET | 14408 | 5.94 |
| 12:56 ET | 1000 | 5.945 |
| 12:57 ET | 3550 | 5.945 |
| 12:59 ET | 2765 | 5.94 |
| 01:01 ET | 1919 | 5.92 |
| 01:03 ET | 2030 | 5.91 |
| 01:06 ET | 20772 | 5.9326 |
| 01:08 ET | 1256 | 5.95 |
| 01:10 ET | 2096 | 5.96 |
| 01:12 ET | 945 | 5.96 |
| 01:15 ET | 2738 | 5.9725 |
| 01:17 ET | 1416 | 5.96 |
| 01:19 ET | 300 | 5.98 |
| 01:26 ET | 700 | 5.98 |
| 01:28 ET | 827 | 5.98 |
| 01:30 ET | 1500 | 5.96 |
| 01:32 ET | 100 | 5.94 |
| 01:33 ET | 1855 | 5.95 |
| 01:37 ET | 100 | 5.94 |
| 01:42 ET | 400 | 5.91 |
| 01:44 ET | 100 | 5.925 |
| 01:46 ET | 1393 | 5.91 |
| 01:48 ET | 756 | 5.91 |
| 01:50 ET | 334 | 5.91 |
| 01:51 ET | 100 | 5.85 |
| 01:55 ET | 200 | 5.83 |
| 01:57 ET | 200 | 5.84 |
| 02:00 ET | 100 | 5.855 |
| 02:02 ET | 873 | 5.86 |
| 02:04 ET | 200 | 5.84 |
| 02:06 ET | 300 | 5.88 |
| 02:08 ET | 200 | 5.9 |
| 02:09 ET | 700 | 5.88 |
| 02:11 ET | 700 | 5.91 |
| 02:13 ET | 400 | 5.9 |
| 02:15 ET | 100 | 5.9 |
| 02:18 ET | 5350 | 5.93 |
| 02:22 ET | 400 | 5.935 |
| 02:24 ET | 1818 | 5.92 |
| 02:26 ET | 100 | 5.91 |
| 02:27 ET | 1400 | 5.9212 |
| 02:29 ET | 1955 | 5.91 |
| 02:31 ET | 100 | 5.89 |
| 02:36 ET | 200 | 5.89 |
| 02:42 ET | 247 | 5.88 |
| 02:44 ET | 200 | 5.88 |
| 02:45 ET | 2000 | 5.9 |
| 02:47 ET | 2122 | 5.885 |
| 02:49 ET | 400 | 5.8787 |
| 02:51 ET | 100 | 5.885 |
| 02:54 ET | 203 | 5.87 |
| 02:56 ET | 100 | 5.87 |
| 02:58 ET | 600 | 5.9 |
| 03:00 ET | 490 | 5.92 |
| 03:02 ET | 560 | 5.915 |
| 03:03 ET | 1900 | 5.9 |
| 03:07 ET | 200 | 5.88 |
| 03:09 ET | 300 | 5.9 |
| 03:12 ET | 441 | 5.88 |
| 03:14 ET | 175 | 5.8839 |
| 03:16 ET | 14686 | 5.81 |
| 03:18 ET | 3328 | 5.8601 |
| 03:20 ET | 404 | 5.86 |
| 03:21 ET | 300 | 5.86 |
| 03:23 ET | 1500 | 5.85 |
| 03:27 ET | 102 | 5.85 |
| 03:30 ET | 717 | 5.88 |
| 03:32 ET | 300 | 5.9 |
| 03:34 ET | 1850 | 5.89 |
| 03:36 ET | 432 | 5.89 |
| 03:38 ET | 2016 | 5.89 |
| 03:39 ET | 3332 | 5.915 |
| 03:41 ET | 2409 | 5.9 |
| 03:43 ET | 997 | 5.9075 |
| 03:45 ET | 6537 | 5.89 |
| 03:48 ET | 300 | 5.88 |
| 03:50 ET | 905 | 5.9 |
| 03:52 ET | 86482 | 6.1 |
| 03:54 ET | 18941 | 6.16 |
| 03:56 ET | 19017 | 6.205 |
| 03:57 ET | 20319 | 6.2 |
| 03:59 ET | 13890 | 6.2 |
Jun 18, 2024
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Candel Therapeutics to Join Russell 3000(R) Index, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 3, 2024
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 184.5M | -4.8x | --- |
Design Therapeutics Inc | 189.3M | -3.2x | --- |
Immutep Ltd | 284.8M | -7.7x | --- |
Acrivon Therapeutics Inc | 179.1M | -2.0x | --- |
Rani Therapeutics Holdings Inc | 191.6M | -2.9x | --- |
Pyxis Oncology Inc | 194.9M | -2.4x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $184.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
